Impact of immunosuppressive regimens on antibody response after COVID-19 vaccination among Thai kidney transplant recipients.

ABSTRACT:

Background

The lower humoral immunity response after the COVID-19 vaccine in kidney transplant recipients (KTR) has been reported in several studies. However, there are few studies on the efficacy of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine compared between various immunosuppressive regimens.

Methods

We conducted a prospective cohort study at Siriraj Hospital, Bangkok, Thailand. Adult KTRs who received two doses of the ChAdOx1 nCoV-19 vaccine at intervals of 3 months were enrolled. Anti-SARS-COV-2 S-RBD-IgG antibody (anti-RBD) was assessed at the one month after the second dose and considered positive if the level ≥50 AU/mL or 7 BAU/mL. The primary outcome was the seropositivity of anti-RBD. The association between type, dose, and level of immunosuppressive regimen and anti

SUBMITTER: Larpparisuth N 

PROVIDER: S-EPMC11808495 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature